NCT06685705View on ClinicalTrials.gov

Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl As Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

January 1, 2026

Conditions
Magnesium SulfateNeostigmineFentanyl
Interventions
DRUG

Magnesium Sulfate and Bupivacaine 0.125%

patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.

DRUG

bupivacaine and Neostigmine

patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally

DRUG

fentanyl and bupivacaine

patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.

All Listed Sponsors
lead

Assiut University

OTHER

NCT06685705 - Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl As Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries | Biotech Hunter | Biotech Hunter